| Factor Information | |
|---|---|
| Data ID | 2693 |
| Factor | Borg dyspnea index |
| Description | There was a significant decrease in Borg dyspnea index in the ASD group compared with baseline, but it did not reach statistical significance in the VSD and PDA groups. |
| Biomarker | NA |
| Classification | E10 (physiological factor - other) |
| Association | |
|---|---|
| Application | prognosis |
| Objective | The potential effect of sildenafil on pulmonary arterial hypertension related to CHD may be associated with shunt location. |
| p Value | 0.041 |
| Conclusion | There was a significant decrease in Borg dyspnea index in the ASD group compared with baseline, but it did not reach statistical significance in the VSD and PDA groups. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 484 |
| CHD Type | isolated CHD |
| CHD Subtype | ASD/VSD/PDA |
| Reference | |
|---|---|
| PMID | 21678455 |
| Year | 2011 |
| Title | The efficacy and safety of sildenafil in patients with pulmonary arterial hypertension associated with the different types of congenital heart disease |
| Sample | ||
|---|---|---|
| Population | adults | |
| Source | 12-week, prospective, open label, multicenter trial | |
| Region | Beijing, China | |
| Method | 12-week, prospective, open label, multicenter trial | |
| Race | Asian | |
| Disease History | N/A | |
| Treatment History | N/A | |
| Group | ASD (12 Weeks)(Treatment) | ASD (Baseline)(Control) |
| Number | 15 | 15 |
| Age | 32.20 ± 6.32 years | 32.20 ± 6.32 years |
| Gender (Male: Female) | 0:15 | 0:15 |
| Marker Level | 1.8 ± 1.0 | 2.6 ± 1.3 |
